| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| IL-12 R beta 1 | HOTAvitag ILB-H82F7 | Biotinylated Human IL-12 R beta 1 / CD212 Protein, Fc,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $380.00 25ug | ||
| IL-12 R beta 1 | HOTAvitag ILB-H52E1 | Biotinylated Human IL-12 R beta 1 / CD212 Protein, His,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | ||
| IL-12 R beta 1 | HOT ILB-H52H9 | Human IL-12 R beta 1 / CD212 Protein, His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $285.00 100ug | ||
| IL-12 R beta 1 | HOT ILB-H5255 | Human IL-12 R beta 1 / CD212 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $310.00 100ug | ||
| IL-12 R beta 1 | Cynomolgus IL-12 R beta 1 Protein, Fc Tag | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $360.00 100ug | |||
| IL-12 R beta 1 | Avitag ILB-C52E2 | Biotinylated Cynomolgus IL-12 R beta 1 / CD212 Protein, His,Avitag™ | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $360.00 25ug | ||
| IL-12 R beta 1 | Avitag ILB-M52E1 | Biotinylated Mouse IL-12 R beta 1 / CD212 Protein, His,Avitag™ | Mouse | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| KLT-1101 | KLT-1101 | Phase 2 Clinical | Kang Litai Pharmaceutical Co Ltd | Leukopenia; Melanoma; Sarcoma, Kaposi; Solid tumours; Thrombocytopenia | Details |
| Edodekin alfa | RO 247472; YM 01C | Phase 2 Clinical | F. Hoffmann-La Roche Ltd, Valeant, Wistar Institute | Abdominal Neoplasms; Asthma; Bacterial Infections; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Graft vs Host Disease; Hepatitis B; Hepatitis C; HIV Infections; Leishmaniasis; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Malaria; Melanoma; Neoplasms; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| RTX-224 | RTX-224 | Phase 2 Clinical | Rubius Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| KB-707 | KB707; KB-707 | Phase 2 Clinical | Krystal Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours | Details |
| ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| Tolododekin Alfa | ANK101; ANK-101 | Phase 1 Clinical | Ankyra Therapeutics Inc | Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Rejection of renal transplantation; Skin Neoplasms; Soft Tissue Injuries; Solid tumours | Details |
| CLN-617 | CLN-617 | Phase 1 Clinical | Cullinan Therapeutics Inc | Solid tumours | Details |
| SON-1010 | SON-1010 | Phase 1 Clinical | Sonnet Biotherapeutics Inc | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Sarcoma; Solid tumours | Details |
| phIL12 GET | Phase 1 Clinical | Institute Of Oncology Ljubljana | Carcinoma, Basal Cell | Details |
